Glembatumumab vedotin

Synonyms: CDX-011 (DOX), CR011,CR011-vcMMAE

Catalog No.D4054 Purity:99%

Glembatumumab vedotin (CDX-011 (DOX), CR011,CR011-vcMMAE) is an antibody-drug conjugate (ADC) composed of an fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB), conjugated to Monomethyl Auristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Glembatumumab vedotin has the potential for use in research of Breast cancer (TNBC) and advanced or metastatic melanoma.

CAS No. 1182215-65-1

Click to purchase products related to Glembatumumab vedotin

Purity & Quality Control

Batch: Purity: 99% Protein concentration: Endotoxin Level: ＜1EU/mg

Biological Activity

Description	Glembatumumab vedotin (CDX-011 (DOX), CR011,CR011-vcMMAE) is an antibody-drug conjugate (ADC) composed of an fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB), conjugated to Monomethyl Auristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Glembatumumab vedotin has the potential for use in research of Breast cancer (TNBC) and advanced or metastatic melanoma.

Description

References
[1] Ott PA, et al. Cancer. 2019 Apr 1;125(7):1113-1123. [2] Keir CH, et al. Expert Opin Biol Ther. 2012 Feb;12(2):259-63.

References

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	1182215-65-1
ADC antiody	Glembatumumab
ADC cytotoxin	MMAE
Formulation	1xPBS
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

* Name Please enter your name.

* Email Please enter your email. Please enter a valid email address.

Phone

* Comments: Please write something to us.